Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OTLK vs AVTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OTLK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

OTLK Overall Winner 6-Pillar Tally: OTLK 3 – 2 AVTX (1 Tie) Matrix Metrics: OTLK 6 – 3 AVTX

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas AVTX carries 54.9/100 (HOLD) at $7.33 (N/M Forward P/E, -161962.7% operating margin).

  • Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -161962.7% operating margin) and revenue trajectory (-99.4% vs. -69.3% YoY).
  • Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OTLK vs AVTX
OTLK NASDAQ Head-to-Head Winner
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
TTM Revenue N/A
Forward P/E 2.9x
Beta / 30D Vol 1.47β · 79% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.48 · SMA50: $0.56
AVTX NASDAQ
Avalo Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.33
-5.54% 1D
Market Cap $445.2M
TTM Revenue $59,000
Forward P/E N/M
Beta / 30D Vol 1.70β · 167% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 68.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.2%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $7.77 · SMA50: $12.09

6-Pillar Scorecard Institutional Category Breakdown (OTLK 3 – 2 AVTX)

Columns: Metric · OTLK · AVTX
1. Valuation Multiples OTLK
Forward P/E 2.9x N/M
Trailing P/E 2.9x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AVTX
Revenue Growth (YoY) -99.4% -69.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $59,000
Market Cap $107.1M $445.2M
3. Profitability & Quality OTLK
Gross Margin N/A N/A
Operating Margin 4781.8% -161962.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -3.6% -33.6%
4. Balance Sheet & Cash Flow AVTX
Cash Generation (TTM) -$56M -$63M
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.2M Net Debt $65M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OTLK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 181.3% (55th %ile) 88.7% (16th %ile)
Put/Call OI Skew 0.26x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OTLK (6) vs AVTX (3)
Institutional Metric OTLK AVTX Criterion Row Edge
Market Capitalization
Scale
$107.1M $445.2M Larger Scale AVTX
Trailing P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Forward P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Revenue Growth (YoY)
Growth
-99.4% -69.3% Higher Growth AVTX
Operating Margin (TTM)
Profitability
4781.8% -161962.7% Higher Margin OTLK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-3.6% -33.6% Higher ROE OTLK
52-Week Range Position
Momentum
10% ($0–$3) 4% ($7–$24) Stronger Trend OTLK
Beta / 30D Volatility
Risk Regime
1.47β · 79% Vol 1.70β · 167% Vol Lower Realized Risk OTLK
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite AVTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $59,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$56M ($7.2M Net Debt) -$63M ($65M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OTLK +16.14 pp
OTLK: -18.82% · AVTX: -34.96%
3M Horizon OTLK +19.42 pp
OTLK: -43.39% · AVTX: -62.81%
6M Horizon OTLK +127.55 pp
OTLK: +72.91% · AVTX: -54.64%
1Y Horizon AVTX +22.8 pp
OTLK: -73.04% · AVTX: -50.24%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OTLK Revenue AVTX Revenue OTLK Op. Margin AVTX Op. Margin Margin Leader
FY2018 $0M $10M -960.1% -503.4% AVTX
FY2019 $10M $10M -445.6% -239.1% AVTX
FY2020 N/A $10M N/A -1087.4% AVTX
FY2021 N/A $10M N/A -1521.6% AVTX
FY2022 N/A $20M N/A -207.4% AVTX
FY2023 N/A $0M N/A -1421.6% AVTX
FY2024 N/A $0M N/A -15535.6% AVTX
FY2025 $0M $0M -4744.3% -123601.7% OTLK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OTLK BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 181.3%
IV Percentile 55th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OTLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVTX BREAKDOWN
133d in phase · OBV DISTRIBUTION
Current IV 88.7%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OTLK Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $445.2M market capitalization and -161962.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OTLK vs AVTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas AVTX carries 54.9/100 (HOLD) at $7.33 (N/M Forward P/E, -161962.7% operating margin). Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -161962.7% operating margin) and revenue trajectory (-99.4% vs. -69.3% YoY). Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVTX leads the Growth & Scale pillar: OTLK posts -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin), compared with AVTX at -69.3% YoY revenue growth and +0.0% YoY earnings growth on $59,000 TTM revenue (N/A gross margin, -161962.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OTLK cumulative revenue shifted N/A while AVTX shifted +100.0%. In operating R&D and SG&A reinvestment, OTLK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVTX.

OTLK screens cheaper on headline valuation multiples. OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OTLK (-3.6% ROE) versus AVTX (-33.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk). By comparison, AVTX carries 88.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 167% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.